Hospital
Benson Hospital Corporation
Benson Hospital Corporation was paid $12.21M by Medicaid between Jan 2018 and Dec 2024, across 142 billing codes. Its largest line is 99284, emergency room visit (serious) — 28% of everything it billed.
33Billing provider infoBENSON HOSPITAL CORPORATION
BENSON, AZ 85602
BENSON, AZ 85602
33aNPI1336118322assigned 03/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.21M
24GClaims244,962
24DCodes billed142
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#40 of 78
Median peer was paid$12.21M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,347 | $1.26M | |
| 2019 | 33,723 | $1.62M | |
| 2020 | 26,501 | $1.67M | |
| 2021 | 35,087 | $1.89M | |
| 2022 | 46,435 | $2.21M | |
| 2023 | 44,176 | $1.98M | |
| 2024incomplete | 33,693 | $1.58M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 9,871 | 8,230 | $3.45M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 14,313 | 12,738 | $3.16M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 4,663 | 3,568 | $1.93M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9.7% | 1,491 | 1,180 | $1.19M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 3,898 | 3,693 | $413K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.3% | 10,221 | 2,491 | $399K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 1,584 | 1,278 | $276K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.9% | 443 | 368 | $227K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 243 | 215 | $161K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 1.1% | 720 | 615 | $131K |
| 80053 | Comprehensive metabolic panel | <1% | 14,345 | 11,526 | $120K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,174 | 1,087 | $99K |
130 more codes
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 171 | $86K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,722 | $76K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,320 | $56K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,179 | $55K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 395 | $44K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,852 | $42K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 294 | $28K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,037 | $22K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 302 | $20K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 194 | $20K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 101 | $16K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,020 | $16K |
| 72110 | <1% | 68 | $13K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,105 | $12K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 14 | $12K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,622 | $11K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 420 | $9K |
| 73630 | <1% | 250 | $7K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,677 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,783 | $7K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,597 | $6K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,123 | $6K |
| 87631 | <1% | 1,637 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,755 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,086 | $5K |
| 73562 | <1% | 134 | $5K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,111 | $5K |
| 0012A | <1% | 119 | $5K | |
| 73030 | <1% | 157 | $5K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 822 | $4K |
| 0011A | <1% | 128 | $4K | |
| 84439 | <1% | 683 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 972 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,173 | $3K |
| 80050 | General health panel | <1% | 13 | $3K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,249 | $3K |
| 97162 | <1% | 90 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 56 | $2K |
| 85610 | <1% | 4,431 | $2K | |
| 83880 | <1% | 1,643 | $2K | |
| 80305 | <1% | 1,644 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,817 | $1K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,124 | $1K |
| 80061 | Lipid panel | <1% | 2,495 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,898 | $1K |
| 0013A | <1% | 32 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 34 | $923.70 |
| 82607 | <1% | 433 | $903.38 | |
| 86403 | <1% | 594 | $746.95 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,694 | $715.21 |
| 73564 | <1% | 20 | $714.64 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,450 | $706.31 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14 | $689.81 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 841 | $611.53 |
| 73130 | <1% | 29 | $587.72 | |
| 73610 | <1% | 69 | $564.38 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 255 | $459.88 |
| 82728 | <1% | 333 | $436.55 | |
| 82803 | <1% | 411 | $429.98 | |
| 81025 | <1% | 758 | $380.76 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,010 | $354.91 |
| 96376 | <1% | 659 | $345.04 | |
| 84484 | <1% | 4,966 | $317.85 | |
| 87400 | <1% | 451 | $302.97 | |
| 90715 | <1% | 28 | $281.81 | |
| 87088 | <1% | 901 | $274.21 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,170 | $245.78 |
| 81003 | <1% | 2,065 | $208.74 | |
| 81001 | <1% | 4,898 | $200.92 | |
| 82043 | <1% | 175 | $200.61 | |
| 85730 | <1% | 2,291 | $196.44 | |
| A9270 | Non-covered item or service | <1% | 5,492 | $184.50 |
| 83020 | <1% | 1,272 | $181.04 | |
| 83735 | <1% | 2,890 | $168.35 | |
| 83690 | <1% | 3,035 | $161.51 | |
| 84703 | <1% | 903 | $154.98 | |
| 83605 | <1% | 3,473 | $131.90 | |
| 87081 | <1% | 29 | $114.59 | |
| 80299 | <1% | 224 | $80.85 | |
| 85651 | <1% | 498 | $77.99 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,643 | $68.46 |
| 99001 | <1% | 41 | $58.20 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,490 | $54.12 |
| 85379 | <1% | 718 | $54.10 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 179 | $50.00 |
| 84481 | <1% | 68 | $40.34 | |
| 83540 | <1% | 354 | $39.66 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 12 | $38.21 |
| 87040 | <1% | 1,483 | $30.02 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 524 | $28.74 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,124 | $25.25 |
| 84145 | <1% | 191 | $24.31 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,480 | $23.47 |
| 82550 | <1% | 497 | $18.88 | |
| 80329 | <1% | 171 | $17.24 | |
| 93040 | <1% | 152 | $16.58 | |
| 87186 | <1% | 1,253 | $13.84 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,046 | $13.08 |
| 82962 | <1% | 61 | $12.96 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,910 | $12.78 |
| 86756 | <1% | 224 | $12.68 | |
| 73080 | <1% | 15 | $12.54 | |
| 82570 | <1% | 75 | $9.64 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 949 | $0.63 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 38 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 51 | $0.00 |
| 97533 | 0% | 27 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 35 | $0.00 |
| 73110 | 0% | 13 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 14 | $0.00 |
| 80076 | 0% | 14 | $0.00 | |
| 97164 | 0% | 21 | $0.00 | |
| 84156 | 0% | 14 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 12 | $0.00 |
| 83550 | 0% | 345 | $0.00 | |
| 86141 | 0% | 17 | $0.00 | |
| 36000 | 0% | 287 | $0.00 | |
| 82150 | 0% | 169 | $0.00 | |
| 86140 | 0% | 406 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 58 | $0.00 |
| 82553 | 0% | 116 | $0.00 | |
| 87077 | 0% | 70 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 136 | $0.00 |
| 91301 | 0% | 213 | $0.00 | |
| 82746 | 0% | 126 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 88 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 89 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 40 | $0.00 |
| 97014 | 0% | 28 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGORANSON, KENNETH (CFO)
| Provider | Location | Paid |
|---|---|---|
| Benson Hospital Corporation | Benson, AZ | $995K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.